Inceptor Bio develops cell therapy solutions to cure difficult-to-treat cancers.
Inceptor Bio has raised $21.0M in total funding. The most recent round was Series A. The last funding was announced in February 2025.
Inceptor Bio's investors include Kineticos Disruptor Fund, Kineticos Life Sciences, Kineticos Ventures.
Inceptor Bio is headquartered in Raleigh, United States.
Inceptor Bio develops cell therapy solutions to cure difficult-to-treat cancers.
Inceptor Bio is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Inceptor Bio — Funding & Investors." VCBacked, February 25, 2025, https://www.vcbacked.co/company/inceptor-bio. Accessed October 28, 2026.
VCBacked. (2025). Inceptor Bio — Funding & Investors. Retrieved October 28, 2026, from https://www.vcbacked.co/company/inceptor-bio
{{cite web |title=Inceptor Bio — Funding & Investors |url=https://www.vcbacked.co/company/inceptor-bio |website=VCBacked |access-date=October 28, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated